Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy

Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy

Both in vivo data in preclinical cancer models and in vitro data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity. Consequently, there is considerable interest in the clinical development of antibody-based therapeutics that...

Full description

Bibliographic Details
Main Authors: Catherine A. Sabatos-Peyton, James Nevin, Ansgar Brock, John D. Venable, Dewar J. Tan, Nasim Kassam, Fangmin Xu, John Taraszka, Luke Wesemann, Thomas Pertel, Nandini Acharya, Max Klapholz, Yassaman Etminan, Xiaomo Jiang, Yu-Hwa Huang, Richard S. Blumberg, Vijay K. Kuchroo, Ana C. Anderson
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
antibody
checkpoint receptor
ligand
tim-3
hdxms
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1385690

Internet

http://dx.doi.org/10.1080/2162402X.2017.1385690

Similar Items